Overview.
Diminished ovarian reserve (DOR) refers to a reduced quantity of oocytes remaining in the ovaries relative to what is expected for age. It is identified through low AMH, elevated basal FSH, and/or low antral follicle count (AFC). DOR does not equal infertility, but significantly reduces the window and responsiveness to fertility treatment. It must be distinguished from Premature Ovarian Insufficiency (POI), a clinically distinct and more serious condition.
Women are born with their full lifetime oocyte supply. AMH, produced by small antral follicles, directly reflects the remaining primordial pool and is cycle-independent — the most sensitive marker. FSH rises only after reserve is significantly depleted (late marker). ASRM 2020 confirms AMH has largely replaced basal FSH as the primary ovarian reserve test. DOR describes below-expected-for-age reserve; POI adds clinical ovarian dysfunction and hypoestrogenism.
Prevalence: Affects 10-30% of women seeking fertility evaluation. Age-related DOR becomes increasingly prevalent after 35. Pathological DOR (unexpectedly low reserve under 35) warrants investigation for reversible or genetic causes.
Medical name: Diminished Ovarian Reserve (DOR)
Symptoms.
Early warnings
- Short menstrual cycles (<25 days, reflecting accelerated follicular recruitment)
- Decreased menstrual flow
- Difficulty conceiving after expected time frame
- Poor response to prior ovarian stimulation
Classic symptoms
- Typically asymptomatic until fertility is impacted
- Short cycles or skipped periods (late finding)
- Reduced response to controlled ovarian stimulation
- Diagnosis often incidental via fertility evaluation or routine testing
Progression
DOR does not improve — ovarian reserve only declines. Without intervention, POI may develop (FSH >25 IU/L, irregular periods, hypoestrogenism). Fertility window narrows progressively. Annual monitoring recommended if in DOR-but-not-POI range.
Risk factors.
- Advanced reproductive age (>35-40) — most common cause
- Endometriosis, especially bilateral ovarian endometriomas
- Prior ovarian surgery (particularly cystectomy for endometriomas)
- Prior chemotherapy (alkylating agents) or pelvic radiation
- FMR1 premutation (fragile X carrier)
- Turner syndrome mosaic
- Autoimmune conditions
- Cigarette smoking (accelerates follicular loss by 1-2 years)
- Single ovary (congenital or surgical)
Lab interpretation.
Key biomarkers
- AMH (Anti-Mullerian Hormone) — Low: <0.5-1.0 ng/mL indicates DOR; POSEIDON cut-off <1.2 ng/mL; cycle-independent but suppressed by hormonal contraception. Does not predict natural conception probability independent from age. (primary)
- Basal FSH (Day 2-5) — Elevated: >10-12 IU/L indicates DOR; specific but insensitive (late marker); high inter-cycle variability. A single low FSH does not exclude DOR. (primary)
- Estradiol (Day 2-5) — Elevated early follicular E2 (>80 pg/mL) can suppress FSH artificially. Always measure alongside FSH. Not an ovarian reserve test in isolation. (primary)
- Antral Follicle Count (AFC) — Low: <5-7 follicles (sum of both ovaries on transvaginal ultrasound day 2-5); equivalent to AMH in predicting oocyte yield in experienced centers (primary)
- Inhibin B — Declines with reserve; less standardized than AMH; not routinely used in clinical practice (secondary)
Diagnostic criteria
- AMH <0.5-1.0 ng/mL (lab and clinical context dependent)
- POSEIDON poor reserve threshold: AMH <1.2 ng/mL or AFC <5
- Basal FSH (day 2-5) >10-12 IU/L
- AFC <5-7 on transvaginal ultrasound
- DOR ≠ POI: POI requires oligo/amenorrhea ≥4 months AND FSH >25 IU/L AND age <40
- No single AMH value definitively predicts inability to conceive
Recommended panels
When & next steps.
When to test
- Planning pregnancy in women over 35 (proactive reserve assessment)
- Difficulty conceiving for >6 months in women over 35 (or >12 months under 35)
- Before ovarian surgery (to counsel on reserve risk)
- History of endometriosis, prior ovarian surgery, chemotherapy, or pelvic radiation
- Family history of early menopause or fragile X
- Prior poor response to ovarian stimulation
- Considering fertility preservation (oocyte cryopreservation)
If suspected
- Order AMH (any day of cycle — most informative single test)
- Add basal FSH + estradiol on cycle day 2-5 for confirmation
- Transvaginal ultrasound for AFC if fertility planning is active
- Withhold interpretation if on hormonal contraception (may suppress AMH)
- In women under 35 with low AMH: add karyotype and FMR1 premutation testing; check FSH/estradiol to assess if POI threshold is crossed
If confirmed
- Counsel urgently on reproductive timeline if fertility desired — reserve does not improve
- Refer to reproductive endocrinology if fertility is a priority
- Discuss fertility preservation: oocyte or embryo cryopreservation
- If POI confirmed: hormone therapy required for bone and cardiovascular protection until age 51
- If DOR without POI: no HRT indicated; monitor FSH annually to detect POI transition
- IVF with donor oocytes has high success rates even with very low AMH
FAQs.
Does having low AMH mean I cannot get pregnant naturally?
No. AMH predicts ovarian response to stimulation (oocyte yield), but does not reliably predict natural conception probability independent from age. Women with low AMH can and do conceive naturally. However, the window is narrower and time is critical — early specialist consultation is recommended.
Will my AMH levels go back up?
No. Once follicles are depleted, ovarian reserve does not regenerate. AMH only declines over time. Experimental interventions like PRP and DHEA have been studied but are not supported by sufficient evidence to change clinical practice.
Is DOR the same as early menopause?
No. DOR means fewer eggs than expected for your age — but if your cycles are regular and FSH is not consistently elevated above 25 IU/L, you do not have POI (premature menopause). DOR is primarily a fertility concern. POI has additional health implications requiring hormone therapy for bone and cardiovascular protection.